Sandbox Reserved 1170: Difference between revisions
From Proteopedia
Jump to navigationJump to search
Whitney Hart (talk | contribs) No edit summary |
Whitney Hart (talk | contribs) No edit summary |
||
| Line 34: | Line 34: | ||
One example of an hGPR40 agonist is TAK-875. TAK-875 has shown efficacy in increasing insulin secretion and lowering blood glucose in rodent models of type 2 diabetes.<ref name="Burant"/> This drug was studied in stage III clinical trials and was able to significantly reduce [[HbA1c]] and fasting plasma glucose levels in Japanese patients with type 2 diabetes that was not controlled by diet and exercise. However, clinical trials were stopped shortly after this study because TAK-875 was suspected of causing liver damage.<ref name="Kaku">PMID:25787200</ref> | One example of an hGPR40 agonist is TAK-875. TAK-875 has shown efficacy in increasing insulin secretion and lowering blood glucose in rodent models of type 2 diabetes.<ref name="Burant"/> This drug was studied in stage III clinical trials and was able to significantly reduce [[HbA1c]] and fasting plasma glucose levels in Japanese patients with type 2 diabetes that was not controlled by diet and exercise. However, clinical trials were stopped shortly after this study because TAK-875 was suspected of causing liver damage.<ref name="Kaku">PMID:25787200</ref> | ||
[[Image:Tak-875.png |300 px|right|Figure Legend]] | |||
<scene name='72/721542/Tak875/2'>Tak-875</scene> | |||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
